Literature DB >> 9747313

[Treatment of mucocutaneous leishmaniasis with pentamidine isothionate].

V Amato, J Amato, A Nicodemo, D Uip, V Amato-Neto, M Duarte.   

Abstract

BACKGROUND: The mucocutaneous form of New World cutaneous leishmaniasis is caused, theoretically, by Leishmania (viannia) braziliensis. Pentad valency antimonic compounds are widely used for treatment of New World cutaneous leishmaniasis. The rate of recurrence is often high when these drugs are used for mucocutaneous forms. Pentamidine has been considered as a second line treatment although little data is available. PATIENTS AND METHODS: Seventeen patients with mucocutaneous leishmaniasis were treated with pentamidine isothionate, 4 mg/kg every 48 hours. A complete oto-rhino-laryngological examination was performed once a week to determine the course of the lesions. Treatment was discontinued when the lesions healed. A follow-up oto-rhinolaryngological examination was also performed after treatment withdrawal and every three months thereafter for an undetermined period.
RESULTS: Lesions healed with pentamidine isothionate in 16 patients (94%). Mean dosage required was 2872 mg (2025-4320 mg) for a mean treatment duration of 22 days (12-32 days). Mean follow-up was 13.3 months (3-37 months). Leishmaniasis relapsed in one patient 4 months after treatment withdrawal. DISCUSSION: Pentamidine isothionate is an effective treatment for mucocutaneous leishmaniasis, providing cure with a low rate of recurrence.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9747313

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  10 in total

1.  Characterization of the gene encoding glyoxalase II from Leishmania donovani: a potential target for anti-parasite drugs.

Authors:  Prasad K Padmanabhan; Angana Mukherjee; Rentala Madhubala
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

Review 2.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 3.  An update on pharmacotherapy for leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Pharmacother       Date:  2014-10-25       Impact factor: 3.889

4.  Characterization of the recent clinical isolates of Indian Kala-azar patients by RAPD-PCR method.

Authors:  Supriya Khanra; Subir K Bandopadhyay; Priyanka Chakraborty; Sanchita Datta; Dinesh Mondal; Mitali Chatterjee; Khudiram Naskar; Syamal Roy; Madhumita Manna
Journal:  J Parasit Dis       Date:  2011-06-24

5.  Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion.

Authors:  Mireille Basselin; Hubert Denise; Graham H Coombs; Michael P Barrett
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  [Cutaneous leishmaniasis--an import from Belize].

Authors:  Jakob Schnedl; Herbert Auer; Marcellus Fischer; Herbert Tomaso; Tom Pustelnik; Gerhard Mooseder
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

7.  Treatment strategies for mucocutaneous leishmaniasis.

Authors:  Emilio Palumbo
Journal:  J Glob Infect Dis       Date:  2010-05

8.  Drug resistance in leishmaniasis.

Authors:  Jaya Chakravarty; Shyam Sundar
Journal:  J Glob Infect Dis       Date:  2010-05

9.  Saraca asoca seed extract treatment recovers the trace elements imbalances in experimental murine visceral leishmaniasis.

Authors:  Sangita Lahiry; Debasish Bhattacharyya; Anindita Chakraborty; Mathummal Sudarshan; Madhumita Manna
Journal:  J Parasit Dis       Date:  2019-10-26

10.  Antileishmanial activity of Urtica dioica extract against zoonotic cutaneous leishmaniasis.

Authors:  Alireza Badirzadeh; Maryam Heidari-Kharaji; Vahid Fallah-Omrani; Hossein Dabiri; Atefeh Araghi; Alireza Salimi Chirani
Journal:  PLoS Negl Trop Dis       Date:  2020-01-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.